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Abstract
The prevalence of drug resistance associated with the failure of non-
nucleoside reverse transcriptase inhibitor (NNRTI)-based regimens
and the predictors of resistance to Etravirine (ETR)were assessed in
2854 subjects: 39 < 18 (paediatric) and 2815  18 (adult) years
old. These subjects failed to respond to their current NNRTI
treatment, were three-class experienced and had been exposed to
NNRTI for  3 months. A total of 1827 adult (64.9%) and 32
paediatric subjects (82.1%) harboured the virus with at least one
ETR mutation. V179I, Y181C and G190A were the most frequent
mutations in both groups. A signiﬁcantly increased risk of ETR
resistance with all three algorithms (Monogram (MGR) >3, Tibotec
(TBT) >2 and enhancedMGR (ENH)  4) emerged in the paediatric
population. Multivariate analysis revealed an increased risk of
developing TBT >2 for NNRTI exposure, ENH  4 for NNRTI and
EFV exposure in paediatric subjects; NVP exposure and higher
( 3.5 log10) HIV-RNA values for all three algorithms in adult
subjects, whereas CD4  200/lL appeared to be protective. The
risk of being ETR resistant was more than doubled for paediatric vs.
adult subjects, probably due to a more extensive use of NNRTI and
an incomplete virological control.
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Etravirine (ETR, TMC125) is a second-generation non-nucle-
oside reverse transcriptase inhibitor (NNRTI) with a potent
activity against wild type and NNRTI-resistant HIV-1 and a high
genetic barrier to the development of resistance [1,2], which
demonstrated its potent antiretroviral activity in the two
DUET phase III studies [3,4]. Tambuyzer and collagues
examined two ETR-weighted genotypic scores (TBT, Tibotec,
Mechelen, Belgium; MGR, Monogram, South San Francisco,
CA, USA), which provided similar results when deﬁning
susceptibility to ETR in treatment-experienced patients and
were able to predict non-response to ETR in c. 60% of subjects
enrolled in the DUET trials [5]. Nevertheless, there is a
difference between mutations associated with ETR use (L100I,
E138G, V179F/I, Y181C/I and H221Y) (i.e. emerge with use of
ETR) and mutations associated with an altered response to
ETR (V90I, A98G, L100I, K101E/H/P, V106I, E138A, V179D/T/
F, Y181C/I/V and G190A/S). In addition to these two
algorithms, a third one, enhanced MGR (ENH), has been
developed [6]. Our study aimed to investigate the prevalence
of drug resistance mutations associated with NNRTI-based
regimen failure and the predictors of resistance to ETR among
subjects included in a large Italian resistance database, including
both paediatric and adult patients.
We retrospectively considered 5547 HIV-1 reverse trans-
criptase sequences obtained from the Italian Antiretroviral
Resistance Cohort Analysis (ARCA; available at www.hivarca.
net) database from a total of 2854 patients experiencing
therapy failure with an NNRTI-based regimen at the time of
drawing and with complete treatment history available. These
subjects had been selected on the basis of having a resistance
test while failing to respond to their antiretroviral regimen
(HIV-RNA >1000 cp/mL). Patients were ETR na€ıve. Inclusion
criteria were an NNRTI-based regimen  3 months, HIV-
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RNA and CD4 cell count available within 1 month before the
resistance test. Drug resistance mutations were interpreted
following the latest IAS-USA panel list proposed as ETR-
speciﬁc (www.iasusa.org, updated in November 2011) [7].
Univariate and multivariate analyses were performed to
estimate crude and adjusted relative risks (odds ratios (Ors),
95% conﬁdence intervals (CIs) and Wald statistic) for gender,
age, HIV-RNA, CD4 cell count, nevirapine, efavirenz, protease
inhibitors (PI) and enfuvirtide (T20) exposure. Moreover, we
considered the number of NNRTI received and the duration of
NNRTI therapy. The level of statistical signiﬁcance was set at
p = 0.05. SPSS 15 for Windows was the statistical software
package used for the analyses. We conducted our analysis by
checking the occurrence of having an MGR score >3, a TBT
score >2 and an ENH score  4, which have been described as
predicting poor virological response to ETR in treatment-
experienced patients.
From the Italian database ARCA (www.hivarca.net), we
selected 5547 sequences from 2854 subjects. Thirty-nine were
<18 (paediatric) years and 2815 were  18 (adult) years old.
Of these 2854 patients, 82.1% (95% CI, 70.0–94.1) of
paediatric and 64.9% (95% CI, 63.1–66.7) of adult subjects
presented at least one mutation for ETR. Among the samples
with at least one mutation for ETR, mutations most frequently
represented were the high weight Y181C (28.2% paediatric,
18.5% adult) and the low weight V179I (30.8% paediatric,
11.2% adult), G190A (23.1% paediatric, 15.1% adult), H221Y
(10.3% paediatric, 6.4% adult) and V106I (10.3% paediatric,
2.5% adult). When we examined the possibility of having an
MGR score >3, a TBT score >2 and an ENH score  4 in the
adult and paediatric population, we found a greater genotypic
resistance among paediatric subjects compared with adults.
According to the MGR score, 48.7% of paediatric subjects had
MGR >3 vs. 31.2% of adult subjects, with an OR with 95% CI of
2.10 (1.1–3.9), p 0.022; for the TBT score, 53.8% of paediatric
subjects had TBT >2 vs. 31.3% of adult subjects, with an OR
(95% CI) of 2.56 (1.4–4.8), p 0.004; ﬁnally an ENH score  4
was found in 59% of pediatric subjects vs. 37.1% of adult
subjects, with an OR (95% CI) of 2.44 (1.3–4.6), p = 0.007.
The overall prevalence of ETR resistance according to the
three different algorithms was 68.4% (TBT >2), 68.5% (MGR
>3) and 62.6% (ENH  4), respectively. Multivariate analysis
revealed an increased risk of developing TBT >2 for NNRTI
exposure, ENH  4 for NNRTI and EFV exposure in pediatric
subjects; NVP exposure and higher ( 3.5 log10) HIV-RNA
values for all three algorithms in adult subjects, whereas
CD4  200/lL appeared to be protective. The number of
subjects in our cohort allowed the estimation of the adjusted
OR (AOR) only in the adult population. As shown in Table 1
(a–c), all three algorithms revealed an increased risk of ETR
resistance for higher HIV-RNA ( 3.5 log10) and for a
previous NVP exposure. T20 experience had a correlation
with ETR resistance, with an AOR of 1.72 (1.00–2.94) only for
the MGR score, whereas CD4 values  200/lL showed a
protection against ETR resistance in both TBT and ENH
scores. The agreement rate of ETR resistance among all three
algorithms evidenced the highest percentage for
MGR+TBT+ENH, with 82.6% for paediatric and 77.2% for
adult subjects (Fig. 1). The ENH algorithm classiﬁed as positive
TABLE 1. (a) Risk of presenting a MGR score >3. (b) Risk of
presenting a TBT score >2. (c) Risk of presenting a ENH score
 4
Age in years
<18  18
OR (95% CI) OR (95% CI) AOR (95% CI)
(a)
Sex
Male 1.35 (0.37–4.92) 1.10 (0.92–1.31) 1.13 (0.95–1.35)
HIV RNA (log10)
<3.5 ^ 1 1 1
3.5–4.5 0.33 (0.02–4.74) 1.76 (1.40–2.22) 1.69 (1.34–2.13)
 4.5 1.33 (0.15–11.93) 1.94 (1.50–2.49) 1.76 (1.34–2.30)
CD4 cells count/lL
<200 ^ 1 1 1
200–399 0.33 (0.01–11.94) 0.69 (0.54–0.88) 0.74 (0.57–0.96)
>400 0.19 (0.01–2.50) 0.66 (0.51–0.84) 0.73 (0.56–0.95)
Per month
NNRTI exposure 1.02 (0.98–1.06) 1.00 (0.99–1.01) 1.00 (0.99–1.01)
NVP exposed 0.73 (0.19–2.79) 1.72 (1.44–2.04) 1.76 (1.41–2.20)
EFV exposed 1.35 (0.37–4.92) 0.75 (0.64–0.88) 1.04 (0.84–1.28)
PI exposed 1.36 (0.39–4.79) 1.04 (0.86–1.27) 0.98 (0.80–1.20)
T20 exposed – 1.95 (1.16–3.28) 1.72 (1.00–2.94)
(b)
Sex
Male 1.50 (0.41–5.54) 1.09 (0.91–1.29) 1.13 (0.95–1.36)
HIV RNA (log10)
<3.5 ^ 1 1 1
3.5–4.5 0.89 (0.09–9.16) 1.57 (1.25–1.97) 1.50 (1.19–1.89)
 4.5 1.33 (0.15–11.93) 1.73 (1.35–2.23) 1.57 (1.20–2.05)
CD4 cells count/lL
<200 ^ 1 1 1
200–399 0.33 (0.01–11.94) 0.71 (0.55–0.91) 0.75 (0.58–0.98)
>400 0.19 (0.01–2.50) 0.65 (0.51–0.83) 0.70 (0.54–0.91)
Per month
NNRTI exposure 1.05 (0.99–1.10) 1.00 (0.99–1.01) 1.00 (1.00–1.01)
NVP exposed 0.63 (0.16–2.43) 1.83 (1.54–2.17) 1.89 (1.51–2.36)
EFV exposed 2.36 (0.62–9.03) 0.73 (0.62–0.86) 1.05 (0.85–1.30)
PI exposed 0.91 (0.26–3.20) 1.06 (0.87–1.29) 1.00 (0.82–1.23)
T20 exposed – 1.80 (1.07–3.05) 1.58 (0.92–2.72)
(c)
Sex
Male 1.69 (0.44–6.47) 1.10 (0.93–1.31) 1.14 (0.96–1.35)
HIV RNA (log10)
<3.5 ^ 1 1 1
3.5–4.5 2.00 (0.19–20.61) 1.50 (1.21–1.86) 1.45 (1.16–1.80)
 4.5 1.33 (0.15–11.93) 1.62 (1.28–2.06) 1.51 (1.17–1.95)
Cd4 cells count/lL
<200 ^ 1 1 1
200–399 0.33 (0.01–11.94) 0.81 (0.64–1.03) 0.86 (0.67–1.10)
>400 0.40 (0.03–5.15) 0.72 (0.57–0.92) 0.78 (0.60–1.01)
Per month
NNRTI exposure 1.05 (0.99–1.11) 1.00 (0.99–1.01) 1.00 (1.00–1.01)
NVP exposed 0.52 (0.13–2.12) 1.56 (1.33–1.84) 1.64 (1.33–2.03)
EFV exposed 4.73 (1.06–21.15) 0.81 (0.69–0.95) 1.08 (0.88–1.33)
PI exposed 0.92 (0.26–3.29) 1.07 (0.89–1.29) 1.02 (0.84–1.24)
T20 exposed – 1.72 (1.02–2.89) 1.53 (0.90–2.61)
^, reference category; 95% CI, 95% Conﬁdence Interval; AOR, adjusted odd ratio;
EFV, efavirenz; ENH, enhanced MGR; MGR, Monogram; Neg, <50 copies/mL.
Signiﬁcant values are in bold characters; NNRTI, nonnucleoside reverse
transcriptase inhibitor; NVP, nevirapine; OR, odd ratio; PI, protease inhibitors;
T20, enfuvirtide; TBT, Tibotec.
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165 subjects not identiﬁed by MGR, whereas TBT classiﬁed as
positive seven subjects not identiﬁed by MGR or ENH.
The DUET studies [8,9] showed that  3 ETR-associated
mutations were required to impair the efﬁcacy of the drug and
Y181C/V, V179F and G190S had the most pronounced effect
on response. The prevalence of the Y181C mutation was
higher in paediatric than in adult subjects (28.2% vs. 18.5%),
together with G190A and V179I. The risk of developing ETR
resistance, according to all algorithms, was more than double
for paediatric compared with adult subjects, probably due to a
more extensive use of NNRTI and an incomplete virological
control. Determinants of genotypic resistance to ETR were
higher HIV-1 RNA values >3.5 log10 and selective NVP
exposure in adult subjects; a detrimental effect of NNRTI and
EFV exposure was shown in pediatric subjects. The difference
between exposure to NVP and EFV might be relevant in
resource-limited settings where NVP is often used. The long-
term use of NVP without an optimized NRTI background
therapy could lead to an accumulation of resistance mutations
[10–12]. This is of particular relevance in situations where
second line HAART regimens are difﬁcult to obtain [13].
Higher levels of immune competence (i.e. CD4  200/Μl)
were protective against future development of ETR genotypic
resistance, thus a new ETR-containing therapeutic line is more
efﬁcient when the immune system is not severely comprom-
ized. The examination of the subjects’ therapeutic history and
the use of these three interpretation algorithms were
demonstrated to be useful in predicting the resistance to
ETR. The adoption of such tools is recommended for
evaluating new antiretrovirals in both paediatric and adult
populations, particularly when therapeutic options may be
limited.
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